Lilly’s total Chinese investment has reached nearly $6 billion, including $3 billion over the next decade to build a localized manufacturing and supply network.
The St. Louis site adds integrated GMP-aligned microbial and ICH-compliant stability testing to improve turnaround times and data visibility, according to the company.
